Credit Suisse raised the price target for the AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) stock from “a Neutral” to “an Underperform”. The rating was released on July 20, 2020. We previously noted in another research note published on November 11, 2019 by Credit Suisse that downgraded the stock from an Outperform to a Neutral with a price target of $2 for ACRX stock. In their research brief published April 24, 2019, B. Riley FBR analysts resumed the AcelRx Pharmaceuticals Inc. stock to Buy with a price target of $6.50.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.1 during the last quarter as opposed to a consensus estimate of -$0.1, which indicates the company missed its estimate by $0, which implies that the company surprised the market by 0.00%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2021) is -$0.08. This is an average of 2 analysts’ earnings, where the high earnings per share estimate is -$0.08 and the low earnings per share estimate is -$0.09. According to 2 analyst estimates, an average revenue estimate of $990k is projected for the current quarter with a high revenue estimate of $1.45M and a low estimate of $520k.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) raised 1.65% to close Friday’s market session at $1.23, higher as compared to yesterday’s close. The stock price fluctuated between $1.19 and $1.2609 throughout the trading session with the volume trading being 1223486 shares, which represented a significant variation when compared to the three months average volume of 4.21 million shares. The firm’s stock price fluctuated 2.50% within the last five trades and -25.45% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -27.22% in the last 6 months and -35.60% was subtracted to its value over the previous 3 months. ACRX stock is trading at a margin of -14.46%, -31.02% and -21.71% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, ACRX deals in the Healthcare domain. The stock is trading -58.16 percent below its 52-week high and 21.78 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -62.28. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does AcelRx Pharmaceuticals Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $156.11 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 34.17. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 28.91 that mirrors the cost to be found for sales by the market.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 1.50 percent of AcelRx Pharmaceuticals Inc. shares are owned by insiders, and 24.60 percent are held by financial institutions. Angotti Vincent J., the Chief Executive Officer at AcelRx Pharmaceuticals Inc. (ACRX) has bought 7,547 shares of firm on Jun 15 at a price of $1.33 against the total amount of $10035.0.